Numeric Investors LLC acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 12,600 shares of the company’s stock, valued at approximately $580,000.

Several other hedge funds also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP boosted its position in shares of Neurocrine Biosciences by 6.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 176,197 shares of the company’s stock worth $8,105,000 after purchasing an additional 10,782 shares in the last quarter. Blue Jay Capital Management LLC bought a new position in shares of Neurocrine Biosciences during the 2nd quarter worth about $6,684,000. Teachers Retirement System of The State of Kentucky boosted its position in shares of Neurocrine Biosciences by 22.5% during the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 58,950 shares of the company’s stock worth $2,712,000 after purchasing an additional 10,844 shares in the last quarter. Senzar Asset Management LLC bought a new position in shares of Neurocrine Biosciences during the 2nd quarter worth about $34,463,000. Finally, Nordea Investment Management AB bought a new position in shares of Neurocrine Biosciences during the 2nd quarter worth about $1,897,000.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) opened at 62.15 on Friday. The company has a 50-day moving average of $58.56 and a 200-day moving average of $51.23. Neurocrine Biosciences, Inc. has a 1-year low of $37.35 and a 1-year high of $63.77. The stock’s market capitalization is $5.48 billion.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Thursday, August 3rd. The company reported ($0.68) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.01). The company had revenue of $6.34 million for the quarter, compared to the consensus estimate of $0.61 million. During the same quarter last year, the business posted ($0.46) EPS. Analysts anticipate that Neurocrine Biosciences, Inc. will post ($2.45) earnings per share for the current fiscal year.

In other Neurocrine Biosciences news, insider Dimitri E. Grigoriadis sold 15,354 shares of the stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $55.00, for a total value of $844,470.00. Following the transaction, the insider now directly owns 123,045 shares in the company, valued at $6,767,475. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Christopher Flint Obrien sold 6,925 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $61.04, for a total transaction of $422,702.00. Following the completion of the transaction, the insider now owns 55,898 shares in the company, valued at $3,412,013.92. The disclosure for this sale can be found here. Insiders sold 132,580 shares of company stock worth $7,440,850 over the last quarter. Insiders own 4.80% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://theolympiareport.com/2017/10/14/numeric-investors-llc-invests-580000-in-neurocrine-biosciences-inc-nbix.html.

Several equities analysts recently weighed in on NBIX shares. Cowen and Company reaffirmed an “outperform” rating and issued a $65.00 price target (up previously from $60.00) on shares of Neurocrine Biosciences in a research report on Wednesday, August 9th. Leerink Swann reaffirmed an “outperform” rating and issued a $72.00 price target (up previously from $67.00) on shares of Neurocrine Biosciences in a research report on Tuesday. BidaskClub raised shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $84.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, October 5th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $69.00 price target (up previously from $66.00) on shares of Neurocrine Biosciences in a research report on Tuesday, October 3rd. Two investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $68.81.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.